Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Neuphoria Therapeutics Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
225 mg BNC210, Placebo
Social Anxiety Disorder
NCT06510504Enrollment370StartAug 2024Primary CompletionSep 2025CompletionSep 2025 - Phase 2Completed
Phase II Study of BNC210 in PTSD
BNC210, Placebo
Post-Traumatic Stress Disorder
NCT02933606Enrollment193StartJun 2016Primary CompletionJul 2018CompletionJul 2018 - Phase 2Completed
A Study of BNC210 in Elderly Patients With Agitation
BNC210, Placebo
Agitation in the Elderly
NCT03548194Enrollment38StartMay 2018Primary CompletionApr 2019CompletionApr 2019 - Phase 2Completed
A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
BNC210, Placebo
Post-Traumatic Stress Disorder
NCT04951076Enrollment212StartJul 2021Primary CompletionJul 2023CompletionAug 2023 - Phase 2Completed
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
225 mg BNC210, 675 mg BNC210
Social Anxiety Disorder
NCT05193409Enrollment151StartFeb 2022Primary CompletionOct 2022CompletionOct 2022 - Phase 1Terminated
A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
BNC101 Solution for Infusion, BNC101 in combination with FOLFIRI
Colorectal Cancer
NCT02726334Enrollment22StartMar 2016Primary CompletionDec 2017CompletionFeb 2018
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | 225 mg BNC210, Placebo | NCT06510504 |
| Phase 2 | Completed | BNC210, Placebo | NCT02933606 |
| Phase 2 | Completed | BNC210, Placebo | NCT03548194 |
| Phase 2 | Completed | BNC210, Placebo | NCT04951076 |
| Phase 2 | Completed | 225 mg BNC210, 675 mg BNC210 | NCT05193409 |
| Phase 1 | Terminated | BNC101 Solution for Infusion, BNC101 in combination with FOLFIRI | NCT02726334 |